Get started
Work

Safety of lorlatinib in subgroups of patients from a phase I/II trial

Year: 2019
Type: article
DOI: 10.1093/annonc/mdz260.064
Authors: E. Felip, B.J. Solomon, B. Besse, T.M. Bauer, R.A. Soo, D.R. Camidge, R. Chiari, A. Bearz, C.-C. Lin, S.M. Gadgeel, E.-H. Tan, T. Seto, G.R. Oxnard, G. Peltz, A. Abbattista, H. Thurm, F. Toffalorio, S-H I Ou, A.T. Shaw
Institutions: Vall d'Hebron Institute of Oncology, Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation, Université Paris-Sud, Institut Gustave Roussy, Sarah Cannon, Tennessee Oncology, National University Hospital, University of Colorado Anschutz, Azienda Ospedaliera di Perugia, National Taiwan University Hospital, University of Michigan, U-M Rogel Cancer Center, National Cancer Centre Singapore, National Hospital Organization Kyushu Cancer Center, Dana-Farber Cancer Institute, Pfizer (United States), University of California, Irvine, Massachusetts General Hospital
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Ariad Pharmaceuticals, Karyopharm Therapeutics, Taiho Pharmaceutical, Clovis Oncology, Five Prime Therapeutics, Kissei, Mirati Therapeutics, BeiGene, Boehringer Ingelheim Japan, Incyte, Calithera Biosciences, Revolution Medicines, Moderna, Natera, Astellas Pharma, Genentech, EMD Serono, Onyx Pharmaceuticals, Novartis Pharma, Pfizer Japan, Chugai Pharmaceutical, Takeda Oncology, Eli Lilly Japan, Ignyta, Foundation Medicine, Janssen Pharmaceuticals, Daiichi Sankyo Europe
OpenAlex ID: W2978314064
FWCI: 0.165
Cites:
Cited by: 1
Related to: 10